Drug Profile
CDX 6114
Alternative Names: CDX-6114; PhenFloLatest Information Update: 27 Feb 2023
Price :
$50
*
At a glance
- Originator Codexis
- Developer Codexis; Nestle Health Science
- Class Enzymes
- Mechanism of Action Enzyme replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I Phenylketonuria
Most Recent Events
- 23 Feb 2023 Codexis and Nestlé Health Science announces intention to submit IND application for Phenylketonuria in the second half of 2023
- 14 Feb 2023 CDX 6114 is still in phase I trials for Phenylketonuria (Aimmune therapeutics pipeline, February 2023)
- 28 Jul 2022 No recent reports of development identified for phase-I development in Phenylketonuria in Australia (PO, Liquid)